Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...
The global hepatitis B diagnostic tests market is on the brink of significant expansion, driven by a surge in disease incidence, heightened awareness campaigns, and rapid advancements in diagnostic ...
Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...
Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...
4d
Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...
Punjab Chief Minister Bhagwant Mann on Saturday tested positive for leptospirosis, a bacterial infection. Doctors said that ...
[1] Tenofovir disoproxil fumarate (Viread, Gilead Sciences, Inc.) is a new addition to the antiretroviral armamentarium. It is an ester-derived prodrug that is converted in vivo by serum and ...
Hepatitis B affects almost 300 million people worldwide, according to GSK, and while NAs to treat it are available – such as Gilead’s polymerase inhibitor Viread (tenofovir) – there is still ...
drugs to treat it are available – such as Gilead’s polymerase inhibitor Viread (tenofovir) – there is still no curative treatment. A functional cure is said to have been achieved if HBsAg is ...
Gilead Sciences is also a big player in other illnesses like viral Hepatitis, where it offers drugs like Epclusa, Vemlidy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback